Re: Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine.
Nersesyan
A K
AK
D001560:Benzidines / Q000009:adverse effects*; D001564:Benzo(a)pyrene / Q000009:adverse effects; D015415:Biomarkers / Q000032:analysis*; D002273:Carcinogens / Q000009:adverse effects*; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics; D002869:Chromosome Aberrations; D015331:Cohort Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D019656:Loss of Heterozygosity; D015162:Micronucleus Tests; D009784:Occupational Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics; D016273:Occupational Exposure; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics
D001560:Benzidines; D015415:Biomarkers; D002273:Carcinogens; C029876:benzidine; D001564:Benzo(a)pyrene